Literature DB >> 26961934

A comprehensive approach to the prevention of central venous catheter complications: results of 10-year prospective surveillance in pediatric hematology-oncology patients.

Simone Cesaro1,2, Mara Cavaliere3, Anna Pegoraro4,3, Piergiorgio Gamba5, Nicola Zadra6, Gloria Tridello4,3.   

Abstract

We report our decennial experience with 1161 newly-placed long-term central venous catheters inserted in 919 hematology-oncology patients for a total of 413,901 CVC-days of observation. Most of the CVCs were partially-implanted, open-ended, Broviac-Hickman type of CVC (95 %). One thousand and twenty-four complications were recorded equal to 2.47 per 1000 CVC-days. The frequency of complications per CVC, the rate of episodes per 1000 CVC-days, and removal rate were malfunction/occlusion 42 %, 1.18/1000, and 2.3 %; mechanical (dislodgement/rupture/kinking) 18.3 %, 0.51/1000, and 77.4 %; bacteremia 14.8 %, 0.42/1000, and 18.6 %; exit-site/tunnel infection 11.5 %, 0.32/1000, and 9.7 %; thrombosis 0.86 %, 0.02/1000, and 30 %; pneumothorax 0.52 %, 0.01/1000, and 0. In multivariate analysis, the risk factors were for mechanical complications, a younger age <6.1 years at CVC insertion (HR 1.8, p = 0.0006); for bacteremia, a double lumen CVC (HR 3.1, p < 0.0001) and the surgical modality of CVC insertion (HR 1.5, p = 0.03); for exit-site/tunnel infection, a double lumen CVC (HR 2.1, p = 0.0003) and a diagnosis of leukemia or lymphoma (HR 1.8, p = 0.01); for malfunction/occlusion, an age <6.1 years (HR 1.6, p = 0.0003), the diagnosis of leukemia or lymphoma (HR 1.9, p < 0.0001) and double lumen CVC (HR 1.33, p = 0.023). The cumulative incidence of premature CVC removal was 29.2 % and the risk factors associated with this event were the surgical modality of CVC insertion (HR 1.4, p = 0.0153) and an age at CVC positioning less than 6.1 years (HR 1.6, p = 0.0025). We conclude that a best-practice set of rules resulted in reduced CVC complications.

Entities:  

Keywords:  Central venous catheter; Complication; Infection; Malfunction; Occlusion; Pediatric malignancy

Mesh:

Year:  2016        PMID: 26961934     DOI: 10.1007/s00277-016-2634-x

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  8 in total

1.  Comparative Study of Complications in CV Catheter Insertion for Pediatric Patients: Real-time Ultrasound-guided Versus Venography-guided Approach.

Authors:  Shuichi Takano; Norio Shimizu; Naruo Tokuyasu; Teruhisa Sakamoto; Soichiro Honjo; Keigo Ashida; Hiroaki Saito; Yoshiyuki Fujiwara
Journal:  Yonago Acta Med       Date:  2018-02-05       Impact factor: 1.641

Review 2.  [Avoidance of complications when dealing with central venous catheters in the treatment of children].

Authors:  D Aprili; T O Erb
Journal:  Anaesthesist       Date:  2017-04       Impact factor: 1.041

3.  Impact of Perioperative Absolute Neutrophil Count on Central Line-Associated Bloodstream Infection in Children With Acute Lymphoblastic and Myeloid Leukemia.

Authors:  Illya Martynov; Joachim Schoenberger
Journal:  Front Oncol       Date:  2021-11-23       Impact factor: 6.244

4.  Factors affecting mechanical complications of central venous access devices in children.

Authors:  Jessica J Zhang; Ramesh M Nataraja; Amiria Lynch; Richard Barnes; Peter Ferguson; Maurizio Pacilli
Journal:  Pediatr Surg Int       Date:  2022-05-05       Impact factor: 2.003

Review 5.  The potential for developing new antimicrobial resistance from the use of medical devices containing chlorhexidine, minocycline, rifampicin and their combinations: a systematic review.

Authors:  Ruth A Reitzel; Joel Rosenblatt; Bahgat Z Gerges; Andrew Jarjour; Ana Fernández-Cruz; Issam I Raad
Journal:  JAC Antimicrob Resist       Date:  2020-02-21

6.  Occult catheter rupture causing episodic symptoms in a patient treated with epoprostenol.

Authors:  Barbara L LeVarge; Anica C Law; Blanche Murphy
Journal:  Pulm Circ       Date:  2018 Jan-Mar       Impact factor: 3.017

7.  Safety of tunneled central venous catheters in pediatric hematopoietic stem cell recipients with severe primary immunodeficiency diseases.

Authors:  Illya Martynov; Jessica Klima-Frysch; Wolfram Kluwe; Christoph Engel; Joachim Schoenberger
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240

8.  The Profile of Microorganisms Responsible for Port-Related Bacteremia in Pediatric Hemato-Oncological Patients.

Authors:  Ewelina Gowin; Bogna Świątek-Kościelna; Przemysław Mańkowski; Danuta Januszkiewicz-Lewandowska
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.